COUPLING OF CYTOTOXIC AGENTS TO MONOCLONAL ANTIBODY

细胞毒剂与单克隆抗体的偶联

• 批准号: 3613230
• 负责人: GARY S DAVID
• 金额: $ 3.02万
• 依托单位: HYBRITECH, INC.
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-09-30 至 1989-03-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3613230
• 关键词: antineoplastics; combination cancer therapy; cytotoxicity; drug metabolism; immunoconjugates; immunological substance; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radionuclide therapy

We shall provide to NCI investigators 111In-antibody radiolabeling kits for imaging purposes. This will permit the investigators to familiarize themselves with the antibodies and to determine the feasibility of using these antibodies in therapeutic systems. We shall provide 90Y labeled monoclonal antibodies for therapeutic programs. We shall develop systems for antibody-based delivery of drugs to tumor targets. We shall demonstrate the in vitro eficacy of the drug-hapten conjugates (i.e., we shall determine retention of drug activity). We shall develop an in vivo delivery system, based on the pharmacokinetics of indium-labeled drug conugate without and with various concentrations of drug reactive antibody. We shall demonstrate tumoricidal efficacy of the delivery system. We shall prepare and submit to NCI personnel pharmaceutical grade reagents for clinical investigations.

我们将向NCI研究人员提供111 In抗体放射性标记试剂盒， 成像目的。 这将使调查人员熟悉 他们自己与抗体，并确定使用的可行性 这些抗体在治疗系统中。 我们将提供90 Y标记的单克隆抗体用于治疗 程序. 我们将开发基于抗体的肿瘤药物输送系统 目标的 我们将证明药物-半抗原偶联物的体外有效性 (i.e.,我们将确定药物活性的保留）。 我们将开发一种体内给药系统，基于药物动力学 不含和含不同浓度的铟标记药物缀合物 药物反应性抗体 我们将证明输送系统的杀肿瘤有效性。 我们将准备并提交给NCI人员医药级试剂 用于临床研究。